Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lawyers Urge Firms To Be Ready For Nanotech Torts, Tougher Inspections

This article was originally published in The Tan Sheet

Executive Summary

Manufacturers of nanotechnology-based products should be on guard for lawsuits filed by employees and an anxious plaintiffs' bar, as well as increased attention from regulatory officials under the new administration, according to lawyers

You may also be interested in...



Obama Says Peanut Butter Problem Points To “Full Review” Of FDA

President Obama plans a "full review" of FDA, saying the agency should be able to act earlier to address problems such as the ongoing recalls related to peanut butter products stop the distribution of contaminated peanut butter ingredients

Nanotech Report’s Recommendations Unsettling To Supplement Industry

Dietary supplement industry groups say an FDA panel's report citing the lack of information about working with nanotechnology should prompt the agency to be cautious about acting on the panel's recommendation to issue a guidance on using nano-materials in new dietary ingredients

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel